Cable Hill Partners LLC Decreases Position in Sanofi (NASDAQ:SNY)

Cable Hill Partners LLC lessened its holdings in Sanofi (NASDAQ:SNY) by 41.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,038 shares of the company’s stock after selling 3,631 shares during the period. Cable Hill Partners LLC’s holdings in Sanofi were worth $243,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its position in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors increased its stake in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after purchasing an additional 751 shares during the period. Geode Capital Management LLC increased its stake in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its stake in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the period. Finally, GFS Advisors LLC increased its stake in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Up 0.1 %

Shares of Sanofi stock opened at $54.95 on Thursday. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company’s 50-day simple moving average is $51.38 and its 200-day simple moving average is $52.58. The firm has a market cap of $139.45 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.